Medications

Post-event Pain algorithm

Pain is a personal, multidimensional experience in which genetic biomarkers has a main role in determining pain sensitivity, perception and tolerance. Pain is a major concern for surgical patients and post-operative pain management still present a major challenge both in inpatient or outpatient settings. Apart from genetic factors, there are many other variables that may affect pain perception for example, pretreated patients may require less post-surgical medications, and they may recover more quickly.

Owner Phenotyping Groups: 
eMERGE CCHMC Group
View Phenotyping Groups: 
eMERGE Phenotype WG
Final

Red Blood Cell Indices

Laboratory results for ESR and RBC indices (hemoglobin, MCV, MCH, RDW… etc) should be extracted from the Laboratory databases. For Mayo, from January 1994 till October 2009, ESR and RBC test results were populated for our 3336 participants. All samples were collected on an outpatient basis. Samples collected during an inpatient hospitalization (admit date ≤ collection date ≤ discharge date) should be excluded unless this sample was the only one available for a patient.

Owner Phenotyping Groups: 
eMERGE Mayo Group
View Phenotyping Groups: 
eMERGE Phenotype WG
Final

Rheumatology Auto-Immune characteristics

Dear,

To identify cases with auto-immune rheumatologic phenotye (for  NT198) we request information about auto-antibody (whether it was tested and what the restults were) and drug information (whether it was prescribed) for each patients that is enrolled in eMERGE. We are requesting every mention of any of the expanded generic drugs.

Owner Phenotyping Groups: 
eMERGE Harvard Group
Final

RxNorm RxCUI codes for Cancer Therapies

This phenotype includes RxNorm RxCUI codes for cancer therapies. These codes map to drug records in the PCORnet Common Data Model and other data sources. The phenotype was developed in 2019. Please see the associated files for additional information. 

The development of this phenotype was supported by a Patient-Centered Outcomes Research Institute (PCORI) Award (No. CDRN-1306-04631) for the development of the national patient-centered clinical research network, known as PCORnet.

Owner Phenotyping Groups: 
GPC
PCORI MidSouth CDRN/Duke Group
Final

SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria

Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.

Owner Phenotyping Groups: 
eMERGE Northwestern Group
View Phenotyping Groups: 
eMERGE Mayo Group
eMERGE Phenotype WG
Final

Systemic lupus erythematosus (SLE)

We used Vanderbilt’s Synthetic Derivative (SD), a de-identified version of the EHR, with 2.5 million subjects. We selected all individuals with at least one SLE ICD-9 code (710.0) yielding 5959 individuals. To create a training set, 200 were randomly selected for chart review. A subject was defined as a case if diagnosed with SLE by a rheumatologist, nephrologist, or dermatologist.

Final

Pages